Company Overview - Jinkai (Liaoning) Life Science Technology Co., Ltd. is located in Fuxin City, Liaoning Province, and was established on June 8, 2009. The company went public on August 3, 2023. Its main business involves providing small molecule CDMO services to global clients in the life sciences sector, assisting pharmaceutical companies with new drug development projects by offering custom development and production services for small molecule drug intermediates and a limited amount of active pharmaceutical ingredients [2]. Financial Performance - For the period from January to June 2025, Jinkai Life Science achieved operating revenue of 348 million yuan, representing a year-on-year growth of 32.98%. The net profit attributable to the parent company was 71.76 million yuan, showing a significant increase of 123.61% compared to the previous year [2]. Shareholder Information - As of September 19, 2025, the number of shareholders in Jinkai Life Science was 14,300, a decrease of 3.65% from the previous period. The average circulating shares per person increased by 3.78% to 3,968 shares [2]. Financing and Trading Activity - On September 23, Jinkai Life Science's stock price fell by 2.46%, with a trading volume of 105 million yuan. The margin trading data indicated a financing purchase amount of 9.33 million yuan and a repayment of 9.64 million yuan, resulting in a net financing outflow of 308,900 yuan. The total margin balance as of September 23 was 140 million yuan, accounting for 6.91% of the circulating market value, which is above the 80th percentile level over the past year [1]. Dividend Distribution - Since its A-share listing, Jinkai Life Science has distributed a total of 117 million yuan in dividends [3]. Institutional Holdings - As of June 30, 2025, two funds, Yuanxin Yongfeng Ju You A and Yuanxin Yongfeng Xing Yuan A, have exited the list of the top ten circulating shareholders of Jinkai Life Science [3].

Core Viewpoint - The report highlights the financial performance and operational capabilities of Kingchem (Liaoning) Life Science Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and net profit, alongside a focus on CDMO services in the life sciences sector [1][3][5]. Financial Performance - The company's revenue for the reporting period reached approximately 348.40 million yuan, representing a 32.98% increase compared to the same period last year, which was approximately 261.99 million yuan [6][16]. - The net profit attributable to shareholders increased by 122.22%, with basic and diluted earnings per share rising to 0.60 yuan from 0.27 yuan [6][16]. - The total assets at the end of the reporting period were approximately 2.30 billion yuan, a 1.78% increase from the previous year [6][16]. Business Overview - Kingchem operates as a small molecule CDMO service provider, catering to global pharmaceutical and biotechnology companies by offering custom development and manufacturing services [8][9]. - The company specializes in the synthesis of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), focusing on enhancing the efficiency and reducing the costs of drug development for its clients [9][10]. Competitive Advantages - The company has established a global presence with production and R&D facilities in both China and the United States, allowing for better responsiveness to client needs and market demands [11][12]. - Kingchem's expertise in fluorinated compounds and a comprehensive range of chemical synthesis capabilities position it as a competitive player in the CDMO market [13][14]. Client Relationships - The company has built a strong client base, including major international pharmaceutical companies and innovative biotech firms, which enhances its business sustainability and growth potential [11][13]. - Long-term partnerships with clients are fostered through high-quality service and adherence to stringent quality management systems, which are critical in the pharmaceutical industry [14]. Research and Development - Kingchem has invested in R&D to support its service offerings, with a focus on developing complex chemical compounds and optimizing production processes [9][13]. - The company has a pipeline of clinical-stage projects, which could lead to significant revenue growth if successful products are brought to market [14].